Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab and All-trans Retinoic Acid for Refractory Pancreatic Cancer
NCT05482451Phase 1Active, not recruiting
- Sponsor
- China Medical University Hospital
- Start
- Mar 2021
- Primary completion
- Feb 2025
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of tretinoin and nivolumab in pancreatic adenocarcinoma (PDAC), sponsored by China Medical University Hospital. Primary endpoint: Overall response up to 2 years. Started Mar 2021; status: active, not recruiting.
02
Drugs
tretinoinnivolumab
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT05482451.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05482451.